AgCl(PPh3)3 | 17116-26-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: AgCl(PPh3)3
• 英文别名: chlorotris(triphenylphosphine)silver(I)；Ag(PPh₃)3Cl；Silver;triphenylphosphane;chloride；silver;triphenylphosphane;chloride
• CAS: 17116-26-6
• 化学式: C₅₄H₄₅AgClP₃
• 分子量: 930.194
• InChiKey: HGRDTYNVLQVGFJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  7.34
• 重原子数：
  59
• 可旋转键数：
  9
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  AgCl(PPh3)3 以 乙醚 、 氘代氯仿 为溶剂， 生成 chloro(triphenylphosphine)silver(I)
  参考文献：
  名称：

  Synthesis, spectroscopy and structural characterization of silver(I) complexes containing unidentate N-donor azole-type ligands

  摘要：

  From the interaction between azole-type ligands L and AgX (X = NO3 or ClO4) or [AgX(PPh3)(n)] (X = Cl, n = 3; X = MeSO3. n = 2), new ionic mononuclear [Ag(L)(2)]X and [Ag(PPh3)(3)L][X] or neutral mono-([Ag(PPh3)(n)L(X)]) or di-nuclear ([{Ag(PPh3)(L)(mu-X)}(2)]) complexes have been obtained which have been characterized through elemental analysis, conductivity measurements, IR, H-1 NMR and, in some cases, also by (31)p{H-1} NMR spectroscopy, and single-crystal X-ray studies. Stoichiometries and molecular structures are dependent on the nature of the azole (steric hindrance and basicity), of the counter ion, and on the number of the P-donor ligands in the starting reactants. Solution data are consistent with partial dissociation of the complexes, occurring through breaking of both Ag-N and Ag-P bonds. (c) 2005 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2005.10.016
• 作为产物：
  描述：

  {AgGe(C6H5)3(triphenylphosphine)3} 以 氯仿 为溶剂， 生成 AgCl(PPh3)3
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Ag: MVol.B7, 1.23.3, page 208 - 220

  摘要：

  DOI：

文献信息

• Copper(I), silver(I), and gold(I) complexes with nido-pentaborane anions
  作者：Norman N. Greenwood、John Staves

  DOI：10.1039/dt9780001144

  日期：——

  The 16-electron copper(I) complexes [Cu(µ-1-BrB5H7)(PPh3)2] and [Cu(µ-B5H8)(dppe)](dppe = Ph2PCH2- CH2PPh2) have been prepared and shown to be similar to [Cu(µ-B5H8)(PPh3)2] whose structure has recently been established by single-crystal X-ray analysis. The corresponding silver(I) complex [Ag(µ-B5H8)(PPh3)2] has been prepared as a colourless photosensitive solid which decomposes fairly rapidly in solution

  16电子铜（I）络合物[Cu（µ-1-BrB 5 H 7）（PPh 3）2 ]和[Cu（µ-B 5 H 8）（dppe）]（dppe = Ph 2 PCH 2- CH 2 PPH 2）已经被制备并且显示出类似物[Cu（μ-B 5 ħ 8）（PPH 3）2 ]，其结构最近被单晶建立X射线分析。相应的银（I）络合物[Ag（µ-B 5 H 8）（PPh 3）2制备成无色的光敏固体，即使在没有光的情况下它也能在溶液中相当快地分解。然而，11 B nmr光谱显示该络合物在二氯甲烷中不易流动。在–78°C形成金络合物，可能是[Au（B 5 H 8）（PPh 3）]，但它太不稳定而无法分离。
• The reactions of AgY salts with [Fe2(η-C5H5)2(CO)4-n(CNMe)n] complexes (Y−  NO3−, BF4− or PF6−; n  0, 1 or 2). The crystal structure of [Fe(η-C5H5)2(CNMe)]BF4
  作者：Brian Callan、A.R. Manning、F.S. Stephens

  DOI：10.1016/0022-328x(87)80008-6

  日期：1987.9

  The oxidative cleavage of [Fe2(η-C5H5)2(CO)4-n(CNMe)n] (n=0−2) by 2AgX gives mononuclear products. It is shown to be a two-electron process in most solvents but a one-electron process in acetonitrile. The two-electron oxidations proceed by way of adducts such as [Fe2(η-C5H5)2(CO)(CNMe)(μ-CO);μ-CN(Me)AgPPh3};]BF4 which are isolable when n = 2, detectable when n = 1 and postulatetd when n = 0. The one-electron

  的氧化裂解的[Fe 2（η-C 5 H ^ 5）2（CO）4- Ñ（CNME）Ñ（Ñ = 0-2）由2AgX给出单核产品。它在大多数溶剂中显示为两电子过程，但在乙腈中为单电子过程。两个电子氧化作用，进行由加合物如的方式的[Fe 2（η-C 5 H ^ 5）2（CO）（CNME）（μ-CO）;μ-CN（Me）的AgPPh 3 };] BF 4当n = 2时是可隔离的，当n = 1时可检测，并且当n时已推后= 0。一个电子过程没有给出加合物和1AgX切割所有的基材的的[Fe（η-C 5 H ^ 5）（CO）（L）（NCMe）] +和[铁（η-C 5 H ^ 5）（CO）（L）] 。（LCO或CNME）。后者可组合或添加CHBr反应3得到的[Fe（η-C 5 H ^ 5）（CO）（L）BR]。的[Fe（η-C的结构5 ħ 5）（CO）2 - （CNME）] BF 4已经通过X射线衍射来确定。
• Reactions and effect of N-sulfonylpyrrole yielding metal complexes: Crystal structural studies
  作者：Winston Nxumalo、Andrew Dinsmore、Richard M. Mampa、Bernard Omondi

  DOI：10.1016/j.poly.2017.03.051

  日期：2017.6

  transition metal salts in low oxidation states, in a basic medium, to afford complexes in different coordination modes ranging from three to five coordinated systems. Complexes of the type NiL2 (2), CuL2 (3), CuL[P(pH3)] (7), AgL[P(pH3)]2 (8), AgL[P(Ph)3] (9), and PtL(COD) (10) with unusual η2,η2 to η2,η1 rearrangement, following double bond migration to form 1,2-η2-σ-cycloocta-1,4-dienyl σ/π coordinating

  摘要N-甲苯磺酰基吡咯与苄腈在室温下反应，得到4-甲基-N- [苯基（1H-吡咯-2基）亚甲基]甲苯磺酰胺（L）。在碱性介质中，使配体（L）与处于低氧化态的选定的第一，第二和第三行过渡金属盐反应，以三至五个配位体系的不同配位模式提供配合物。NiL2（2），CuL2（3），CuL [P（pH3）]（7），AgL [P（pH3）] 2（8），AgL [P（Ph）3]（9）和在双键迁移形成1,2-η2-σ-环辛-1,4-二烯基σ/π双齿配体之后，获得了具有不寻常的η2，η2至η2，η1重排的PtL（COD）（10）。L在过量DBU的存在下反应，得到CoL2（DBU）（4）和ZnL2（DBU）（5）型的双配位配合物。所有化合物的结构特征均采用不同的技术，包括1H和13C NMR，UV-Vis，IR，质谱和元素分析。配体L和配合物4、7、8、9和10的分子结构通过X射线衍射分析确定。在所有金属络合物
• Synthesis and Structural Characterization of Silver(I) and Gold(I) Complexes with 2-Mercaptonicotinic Acid (H₂mna) and Triphenylphosphine Ligands, and Their Antimicrobial Activities. Crystal Structures of Monomeric, 3- and 4-Coordinate Silver(I) Complexes [Ag(Hmna)(PPh₃)₂] and [Ag(Hmna)(PPh₃)₃] in the Solid State
  作者：Kenji Nomiya、Ryusuke Noguchi、Takaye Shigeta、Yoshihiro Kondoh、Kazuhiro Tsuda、Katsunori Ohsawa、Noriko Chikaraishi-Kasuga、Munehiro Oda

  DOI：10.1246/bcsj.73.1143

  日期：2000.5

  Two types of silver(I)-triphenylphosphine complexes with 2-mercaptonicotinic acid (H2mna) were prepared as [Ag(Hmna)(PPh3)n] (1, n = 2; 2, n = 3); their crystal structures determined by single-crystal X-ray diffraction. These complexes were obtained from reactions of the precursor, [Ag(Hmna)]n, with less excess (3 equiv) and large excess (20 equiv) amounts of PPh3, respectively. Complex 1 was also obtained

  制备了两种类型的银 (I)-三苯基膦与 2-巯基烟酸 (H2mna) 络合物为 [Ag(Hmna)(PPh3)n] (1, n = 2; 2, n = 3); 它们的晶体结构由单晶 X 射线衍射确定。这些配合物分别由前体 [Ag(Hmna)]n 与少量过量 (3 当量) 和大量过量 (20 当量) PPh3 的反应获得。配合物 1 也是从另一种前体 [AgCl(PPh3)3]、H2mna 和 NaOH 水溶液之间的反应中获得的。1 的配位几何是具有 AgSP2 核心的三角金字塔；银 (I) 中心和吡啶氮原子之间存在弱相互作用，而 2 是具有 AgSP3 核心的扭曲四面体。在 1 和 2 中，羧基被质子化，其氧原子不参与配位。
• [EN] USE OF SILVER (I) COMPLEXES AS ANTICANCER AGENTS<br/>[FR] UTILISATION DE COMPLEXES D'ARGENT (I) EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：UNIV JOHANNESBURG

  公开号：WO2013084185A1

  公开（公告）日：2013-06-13

  The present invention relates to the use of silver(l) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.

  本发明涉及将银（I）单膦配合物用作活性药用成分（API），包括抗癌药物，用于治疗、诊断和/或预防癌症。本发明还涉及含有这种配合物的药物组合物，并进一步扩展到治疗或诊断患有癌症的受试者/患者的方法。